Research ExplorerPublicationsN-Terminal pro-brain natriuretic peptide: normal ranges in t...

N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability.

Standard

N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. / Albers, Stefanie; Mir, Thomas; Haddad, Munif; Läer, Stephanie.

In: CLIN CHEM LAB MED, Vol. 44, No. 1, 1, 2006, p. 80-85.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Albers, S, Mir, T, Haddad, M & Läer, S 2006, 'N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability.', CLIN CHEM LAB MED, vol. 44, no. 1, 1, pp. 80-85. https://doi.org/10.1515/CCLM.2006.016

APA

Albers, S., Mir, T., Haddad, M., & Läer, S. (2006). N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. CLIN CHEM LAB MED, 44(1), 80-85. [1]. https://doi.org/10.1515/CCLM.2006.016

Vancouver

Albers S, Mir T, Haddad M, Läer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. CLIN CHEM LAB MED. 2006;44(1):80-85. 1. https://doi.org/10.1515/CCLM.2006.016

Bibtex

@article{fd317dc84085492590cb2c0ce5b4db23,
title = "N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability.",
abstract = "The aim of the present study was the investigation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the pediatric population. This is essential for adequate monitoring and classification of pediatric patients with heart disease, but no consistent data are available yet. In addition, the comparability of two commercially available NT-proBNP assays and the inter-laboratory variability for the most suitable one were assessed. For this purpose, 408 subjects (1-29 years) were included. NT-proBNP was determined with a non-competitive electrochemiluminescent immunoassay (Roche NT-proBNP; n = 402) and a competitive enzyme-immunoassay (Biomedica NT-proBNP; n = 402). Inter-laboratory variability was evaluated for the Roche assay by stepwise inclusion of four and 11 centers throughout Germany, respectively. Roche NT-proBNP ranged from 5.0 to 391.5 ng/L, with higher values for younger children. The 97.5th (75th) percentile curve ranged from 319.9 ng/L (231.2 ng/L, 1-3 years) to 114.9 ng/L (53.3 ng/L, 18 years). In contrast, Biomedica NT-proBNP ranged from 253.7 to 7602.8 ng/L, with no significant age dependency. The mean difference between the assays was 1649.7 ng/L (95% confidence interval 1546.3-1753.1 ng/L). Inter-laboratory variability ranged from 6.5% to 3.8%, covering a range from 51.3 to 6618.1 ng/L. The assay seems to influence the interpretation of resulting NT-proBNP values and therefore has to be chosen carefully. For the monitoring and classification of pediatric patients with congenital heart disease, age-based NT-proBNP values should be used.",
keywords = "Adolescent, Adult, Age Distribution, Chemistry, Clinical/methods, Child, Child, Preschool, Female, Humans, Infant, Laboratories, Male, Natriuretic Peptide, Brain/blood, Peptide Fragments/blood, Reference Values, Reproducibility of Results",
author = "Stefanie Albers and Thomas Mir and Munif Haddad and Stephanie L{\"a}er",
year = "2006",
doi = "10.1515/CCLM.2006.016",
language = "English",
volume = "44",
pages = "80--85",
journal = "CLIN CHEM LAB MED",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

RIS

TY - JOUR

T1 - N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability.

AU - Albers, Stefanie

AU - Mir, Thomas

AU - Haddad, Munif

AU - Läer, Stephanie

PY - 2006

Y1 - 2006

N2 - The aim of the present study was the investigation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the pediatric population. This is essential for adequate monitoring and classification of pediatric patients with heart disease, but no consistent data are available yet. In addition, the comparability of two commercially available NT-proBNP assays and the inter-laboratory variability for the most suitable one were assessed. For this purpose, 408 subjects (1-29 years) were included. NT-proBNP was determined with a non-competitive electrochemiluminescent immunoassay (Roche NT-proBNP; n = 402) and a competitive enzyme-immunoassay (Biomedica NT-proBNP; n = 402). Inter-laboratory variability was evaluated for the Roche assay by stepwise inclusion of four and 11 centers throughout Germany, respectively. Roche NT-proBNP ranged from 5.0 to 391.5 ng/L, with higher values for younger children. The 97.5th (75th) percentile curve ranged from 319.9 ng/L (231.2 ng/L, 1-3 years) to 114.9 ng/L (53.3 ng/L, 18 years). In contrast, Biomedica NT-proBNP ranged from 253.7 to 7602.8 ng/L, with no significant age dependency. The mean difference between the assays was 1649.7 ng/L (95% confidence interval 1546.3-1753.1 ng/L). Inter-laboratory variability ranged from 6.5% to 3.8%, covering a range from 51.3 to 6618.1 ng/L. The assay seems to influence the interpretation of resulting NT-proBNP values and therefore has to be chosen carefully. For the monitoring and classification of pediatric patients with congenital heart disease, age-based NT-proBNP values should be used.

AB - The aim of the present study was the investigation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the pediatric population. This is essential for adequate monitoring and classification of pediatric patients with heart disease, but no consistent data are available yet. In addition, the comparability of two commercially available NT-proBNP assays and the inter-laboratory variability for the most suitable one were assessed. For this purpose, 408 subjects (1-29 years) were included. NT-proBNP was determined with a non-competitive electrochemiluminescent immunoassay (Roche NT-proBNP; n = 402) and a competitive enzyme-immunoassay (Biomedica NT-proBNP; n = 402). Inter-laboratory variability was evaluated for the Roche assay by stepwise inclusion of four and 11 centers throughout Germany, respectively. Roche NT-proBNP ranged from 5.0 to 391.5 ng/L, with higher values for younger children. The 97.5th (75th) percentile curve ranged from 319.9 ng/L (231.2 ng/L, 1-3 years) to 114.9 ng/L (53.3 ng/L, 18 years). In contrast, Biomedica NT-proBNP ranged from 253.7 to 7602.8 ng/L, with no significant age dependency. The mean difference between the assays was 1649.7 ng/L (95% confidence interval 1546.3-1753.1 ng/L). Inter-laboratory variability ranged from 6.5% to 3.8%, covering a range from 51.3 to 6618.1 ng/L. The assay seems to influence the interpretation of resulting NT-proBNP values and therefore has to be chosen carefully. For the monitoring and classification of pediatric patients with congenital heart disease, age-based NT-proBNP values should be used.

KW - Adolescent

KW - Adult

KW - Age Distribution

KW - Chemistry, Clinical/methods

KW - Child

KW - Child, Preschool

KW - Female

KW - Humans

KW - Infant

KW - Laboratories

KW - Male

KW - Natriuretic Peptide, Brain/blood

KW - Peptide Fragments/blood

KW - Reference Values

KW - Reproducibility of Results

U2 - 10.1515/CCLM.2006.016

DO - 10.1515/CCLM.2006.016

M3 - SCORING: Journal article

C2 - 16375591

VL - 44

SP - 80

EP - 85

JO - CLIN CHEM LAB MED

JF - CLIN CHEM LAB MED

SN - 1434-6621

IS - 1

M1 - 1

ER -